Dose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over study

BACKGROUND: Umeclidinium bromide (UMEC) is an inhaled long-acting muscarinic antagonist in development for chronic obstructive pulmonary disease (COPD). METHODS: This was a multicentre, randomised, double-blind, placebo-controlled, three-way cross-over, incomplete block study to evaluate UMEC 15.6,...

Descripción completa

Detalles Bibliográficos
Autores principales: Church, Alison, Beerahee, Misba, Brooks, Jean, Mehta, Rashmi, Shah, Palvi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4029330/
https://www.ncbi.nlm.nih.gov/pubmed/24393134
http://dx.doi.org/10.1186/1471-2466-14-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4029330/
https://www.ncbi.nlm.nih.gov/pubmed/24393134
http://dx.doi.org/10.1186/1471-2466-14-2

Ejemplares similares